Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00750334
NCT00750334TerminatedPhase 1

A Phase I, Open-Label, Dose-Finding and Food Effect Study of Oral Clofarabine in Previously Treated Adult Patients With Myelodysplastic Syndromes (MDS)

Genzyme, a Sanofi Company3 sites in 1 country2 target enrollmentStarted: September 2008Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 1
Status
Terminated
Sponsor
Enrollment
2
Locations
3
Primary Endpoint
Maximum Tolerated dose levels
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This study will be used to determine the maximum tolerated dose of oral clofarabine when administered daily for 14 consecutive days repeated every 21 days.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Provide signed, written informed consent.
  • •Be at least 18 years old.
  • •Have a pathologically confirmed MDS and score according to the IPSS at study entry. Pathologic confirmation is the responsibility of the investigator.
  • •Have been treated previously for MDS as follow: a.Patients must have had at least 1, but no more than 2, prior treatment regimens; b.Patients must not have refractory (i.e., disease progression or no evidence of response while on treatment) to more than 1 prior treatment regimen.
  • •Have Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
  • •Be able to comply with study procedures and follow-up examinations.
  • •Have adequate hepatic and renal function.
  • •Be non-fertile or agree to use birth control during the study through the end of the last treatment visit and at least 90 days after.

Exclusion Criteria

  • •Have had a readjustment of dose and/or schedule of erythropoietin, granulocyte colony stimulating factor(G-CSF) or other growth factors within 8 weeks prior to the first dose of oral clofarabine.
  • •Have had any other chemotherapy or any investigational therapy for MDS within 4 weeks of the first dose of oral clofarabine.
  • •Have not recovered to ≤ Grade 2 in severity of any drug-related non-hematologic toxicity prior to the first dose of oral clofarabine.
  • •Have an uncontrolled systemic fungal, bacterial, viral or other infection. Have a history of serious disease involving the heart.
  • •Have a clinically significant cardiac assessment at screening or a known family history QT prolongation.
  • •Currently uses a medication known to prolong the QT interval.
  • •Have had any prior treatment with clofarabine (IV or oral).
  • •Have had a diagnosis of another malignancy, unless the patient has been disease free for at least 3 years after completing curative intent therapy except for the following: a. Patients with treated non-melanoma skin cancer, in situ carcinoma, or cervical intraepithelial neoplasia, regardless of the disease-free duration, are eligible for this study if definitive treatment or the condition has been completed. b. Patients with organ-confined prostate cancer with no evidence of recurrent or progressive disease based on prostate specific antigen (PSA) values are also eligible for this study if hormonal therapy has been initiated or a radical prostatectomy has been performed.
  • •Have prior positive test for the human immunodeficiency virus (HIV).
  • •Have gastrointestinal disease or prior surgery, which may affect the ability of the patient to absorb oral clofarabine.
  • •Is currently participating in another concurrent investigational protocol that is not restricted to data and/or sample collection for patient demographic and/or disease purposes.

Arms & Interventions

Part A

Experimental

clofarabine Dose Escalation

Intervention: clofarabine (Drug)

Part B

Experimental

Part B is an open-label, replicated cross-over study in which 12 additional patients will be enrolled and treated at the MTD determined in part A to evaluate the effect of food on the PK disposition of oral clofarabine.

Intervention: clofarabine (Drug)

Outcomes

Primary Outcomes

Maximum Tolerated dose levels

Time Frame: First Cycle

Secondary Outcomes

  • PK profile(After MTD is established)
  • Food effect on profile(After MTD is established)
  • Activity of clofarabine in this dosing regimen(Duration of Study)

Investigators

Sponsor
Genzyme, a Sanofi Company
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (3)

Loading locations...

Similar Trials

Withdrawn
Phase 1
Oral Clofarabine in Chronic Lymphocytic Leukemia (CLL)Chronic Lymphocytic LeukemiaLeukemia
NCT00800566M.D. Anderson Cancer Center
Terminated
Phase 1
Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic LeukemiaCancerChronic Myelomonocytic Leukemia
NCT00708721University of Utah11
Completed
Phase 1
Safety of Clofarabine With Multiagent Chemotherapy in Childhood Acute Lymphoblastic LeukemiaAcute Lymphoid Leukemia RelapseAcute Lymphoid Leukemia Relapse After Bone Marrow Transplant
NCT01279096University Hospital, Lille20
Terminated
Phase 1
Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute LeukemiasAcute Promyelocytic LeukemiaMyeloproliferative DisordersAcute Lymphocytic LeukemiaAcute Myeloid LeukemiaMyelodysplastic SyndromeAcute LeukemiaChronic Myelogenous LeukemiaChronic Myelomonocytic LeukemiaMyelofibrosisJuvenile Myelomonocytic Leukemia
NCT00852709Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins35
Completed
Phase 1
Phase I Trial of Clofarabine in Combo w/ HD Etoposide & Cyclophosphamide and APBSCT for Pts w/ High-Risk or Refractory NHLNon Hodgkin's Lymphoma
NCT00477945Indiana University School of Medicine18